Drugs for Conversion of Atrial Fibrillation



FREE PREVIEW Log in or buy this issue to read the full article. AAFP members and paid subscribers get free access to all articles. Subscribe now.


FREE PREVIEW Subscribe or buy this issue. AAFP members and paid subscribers get free access to all articles.

Am Fam Physician. 1998 Aug 1;58(2):471-480.

ACF  This article exemplifies the AAFP 1997–98 Annual Clinical Focus on prevention and management of cardiovascular disease

Atrial fibrillation is the most common arrhythmia in patients visiting a primary care practice. Although many patients with atrial fibrillation experience relief of symptoms with control of the heart rate, some patients require restoration of sinus rhythm. External direct current (DC) cardioversion is the most effective means of converting atrial fibrillation to sinus rhythm. Pharmacologic cardioversion, although less effective, offers an alternative to DC cardioversion. Several advances have been made in antiarrhythmic medications, including the development of ibutilide, a class III antiarrhythmic drug indicated for acute cardioversion of atrial fibrillation. Other methods of pharmacologic and nonpharmacologic cardioversion remain under development. Until the results of several large-scale randomized clinical trials are available, the decision to choose cardioversion or maintenance of sinus rhythm must be individualized, based on relief of symptoms and reduction of the morbidity and mortality associated with atrial fibrillation.

Atrial fibrillation is the most common sustained arrhythmia encountered in primary care practice. According to the Framingham Heart Study,1 atrial fibrillation has a prevalence of 4 percent in the adult population. As the patient population continues to age, the prevalence of this arrhythmia rises as well, from less than 0.05 percent in patients 25 to 35 years of age to more than 5 percent in patients over 69 years of age.2

Atrial fibrillation is associated with significant morbidity, including an increased susceptibility to embolic stroke. It is estimated that the annual risk of stroke in patients with atrial fibrillation is as high as 4.5 percent.3 Atrial fibrillation also can decrease exercise tolerance and has been associated with tachycardia-induced cardiomyopathy. Although many patients with atrial fibrillation are symptomatic, some patients remain asymptomatic. Thus, it is often difficult to estimate the onset, duration or severity of atrial fibrillation by the history alone. Furthermore, treatment strategies vary, depending on the patient's symptoms and clinical syndrome.

Major goals of therapy include prevention of stroke and cardiomyopathy, reduction of symptoms and overall improvement in survival. Management includes heart rate control, rhythm control, anticoagulation therapy, or a combination of these strategies.

Initial treatment also depends on the course of atrial fibrillation. Atrial fibrillation may be divided into acute and chronic forms. There are three types of chronic forms: paroxysmal, persistent and permanent. Paroxysmal atrial fibrillation is defined as recurrent episodes of spontaneously terminating atrial fibrillation. Persistent atrial fibrillation is defined by persistence of the arrhythmia until cardioversion is performed. Permanent atrial fibrillation is refractory to attempts at cardioversion. Thus, cardioversion is used only in cases of acute and chronic persistent atrial fibrillation and not in cases previously demonstrated to be refractory.

Pathophysiology

The electrophysiologic mechanism for atrial fibrillation appears to be multiple wavelets of reentry.4 To allow multiple reentrant wavelets to propagate, a critical mass of excitable tissue must exist. Also, reentrant wavelets must never encounter refractory tissue left over by a previous wavelet, or the wavelets will extinguish and the arrhythmia will not be sustained. Thus, if the refractory period of the atrial myocardium is short (i.e., faster recovery) or if the conduction time is so slow that the tissue can recover before the wavelet arrives, atrial fibrillation can develop.

Several pathophysiologic factors favor the initiation and maintenance of atrial fibrillation (Table 1). Processes that increase atrial size, such as valvular heart disease, ischemic heart disease and dilated cardiomyopathy, provide a greater surface area for the development of multiple reentrant wavelets. Electrolyte abnormalities, ischemia, fibrosis or inflammation may decrease conduction velocity.

TABLE 1

Pathophysiologic Factors that Promote Atrial Fibrillation

Increased atrial size as a result of:

Valvular heart disease

Ischemic heart disease

Cardiomyopathy

Reduced refractory period as a result of:

Increased vagal tone

Increased sympathetic tone

Thyrotoxicosis

Electric remodeling

Decreased conduction velocity as a result of:

Electrolyte abnormalities

Ischemia

Fibrosis and inflammation

Increased vagal tone

Decreased sympathetic tone


note: Class I and class III antiarrhythmic agents both increase the atrial refractory period (a desired effect) and decrease the conduction velocity (an undesired effect). This may account for the mixed efficacy of our current antiarrhythmic medications.

TABLE 1   Pathophysiologic Factors that Promote Atrial Fibrillation

View Table

TABLE 1

Pathophysiologic Factors that Promote Atrial Fibrillation

Increased atrial size as a result of:

Valvular heart disease

Ischemic heart disease

Cardiomyopathy

Reduced refractory period as a result of:

Increased vagal tone

Increased sympathetic tone

Thyrotoxicosis

Electric remodeling

Decreased conduction velocity as a result of:

Electrolyte abnormalities

Ischemia

Fibrosis and inflammation

Increased vagal tone

Decreased sympathetic tone


note: Class I and class III antiarrhythmic agents both increase the atrial refractory period (a desired effect) and decrease the conduction velocity (an undesired effect). This may account for the mixed efficacy of our current antiarrhythmic medications.

Increased sympathetic activity and increased vagal tone decrease the atrial refractory period, as does thyrotoxicosis. These factors may therefore predispose patients to develop atrial fibrillation. Likewise, atrial fibrillation may be terminated by increasing the conduction velocity or increasing the refractory period of the atrial tissue. Antiarrhythmic medications may be of benefit by prolonging the refractory period of atrial tissue, thus preventing propagation of multiple reentry wavelets in the atria. Unfortunately, antiarrhythmic medications also decrease conduction velocity, therefore favoring atrial fibrillation, which may account for the mixed efficacy of antiarrhythmic medications in maintaining sinus rhythm.

If the decision is made for a patient to undergo cardioversion, the procedure should be performed as close to the onset of arrhythmia as possible. Sustained atrial fibrillation causes “remodeling” of the atria, including fibrosis and a decrease of the atrial refractory period. These changes favor the initiation and maintenance of atrial fibrillation. To quote Allessie,4 “Atrial fibrillation begets atrial fibrillation.”

Treatment of Acute Atrial Fibrillation: Rate and Rhythm Control

The goals of therapy in patients presenting with acute onset of atrial fibrillation are to improve hemodynamic instability, decrease the risk of cardioembolic events and improve symptoms. An algorithm for the acute management of atrial fibrillation is given in Figure 1. Patients who are unstable (i.e., a heart rate of 150 or more with low blood pressure, angina pectoris, shortness of breath, decreased level of consciousness, shock, pulmonary congestion, congestive heart failure or acute myocardial infarction) during atrial fibrillation require immediate cardioversion using a 200-joule synchronized shock (preferably with effective conscious sedation).

FIGURE 1.

An algorithm for the acute management of atrial fibrillation. (DC = direct current)

View Large


FIGURE 1.

An algorithm for the acute management of atrial fibrillation. (DC = direct current)


FIGURE 1.

An algorithm for the acute management of atrial fibrillation. (DC = direct current)

In stable patients, control of the heart rate often provides relief of symptoms. However, some patients remain symptomatic despite a controlled heart rate. It is often desirable to restore sinus rhythm in these patients. Unfortunately, it is not known whether restoration of sinus rhythm improves survival, reduces morbidity or even decreases the risk of embolic events.5

Restoration and maintenance of sinus rhythm often require the use of antiarrhythmic medications that carry a risk of proarrhythmia. These drugs may precipitate monomorphic ventricular tachycardia, polymorphic ventricular tachycardia (torsades de pointes) and conversion of atrial fibrillation to atrial flutter with a rapid ventricular response.6 The risk of ventricular proarrhythmia is highest in patients with poor ventricular function.7

Currently, three multicenter randomized trials are under way comparing the treatment of atrial fibrillation by ventricular rate control versus rhythm control (Pharmacologic Intervention in Atrial Fibrillation [PIAF], Rate Control versus Electrical Cardioversion [RACE] and Atrial Fibrillation Follow-up Investigation of Rhythm Management [AFFIRM]).8 The results of these trials will determine the appropriate role of these two treatment strategies in patients with atrial fibrillation.

External direct current (DC) cardioversion is the most effective means of cardioverting atrial fibrillation to sinus rhythm. The risk of proarrhythmia during DC cardioversion is very low. Unfortunately, electric cardioversion is painful and requires the use of conscious sedation. [corrected] In patients with atrial fibrillation refractory to external direct current cardioversion, internal transvenous cardioversion is an alternative means of restoring sinus rhythm. Although this method is safe and effective, it requires the placement of transvenous shocking coils into the right ventricle and the right atrium. Pharmacologic cardioversion using intravenous or oral class I or class III antiarrhythmic agents may be used instead of DC cardioversion.

Prevention of Embolic Events During Cardioversion

Both electric and pharmacologic cardioversion carry a risk of embolic events, including stroke. However, the risk is very small in patients who have been in atrial fibrillation for less than 48 hours. In a study of 357 patients who underwent cardioversion, only three patients (all older than 80 years) had thromboembolic events (0.8 percent).9 Patients with persistent atrial fibrillation of unknown duration or more than 48 hours' duration should be treated with anticoagulants for three weeks before either pharmacologic or DC cardioversion is attempted. Anticoagulation should be continued for four weeks after cardioversion, since the atria require several weeks to recover normal contractile function in this situation.10 The International Standardized Ratio (INR) should be maintained between 2.0 and 3.0.10,11

Transesophageal echocardiography may be used to exclude the presence of thrombus in the atria of patients being considered for cardioversion.12 Using a decision-analytic model, guided cardioversion with transesophageal echocardiography appeared to be a more cost-effective alternative to conventional therapy.13 However, these results must be viewed with caution since embolic events have been reported despite a negative result on transesophageal echocardiography.14 Therefore, a negative transesophageal echocardiogram does not obviate the need for at least a short course of warfarin (Coumadin) therapy after cardioversion.

Pharmacologic Methods of Ventricular Rate Control

When a patient is in atrial fibrillation, one of the first goals of therapy should be control of the ventricular rate. This can be accomplished using calcium channel blockers such as diltiazem (Cardizem) or verapamil (Calan, Isoptin), beta blockers such as metoprolol (Lopressor) or esmolol (Brevibloc), or digoxin (Lanoxin).

Intravenous calcium channel blockers and beta blockers have the advantage of rapid onset of action (Table 2). Digoxin, which is perhaps the oldest form of therapy for atrial fibrillation, has an onset of action between 30 minutes and two hours, with peak effect in two to six hours. Its effects are primarily mediated through the autonomic nervous system.15 At therapeutic doses, vagal tone is enhanced by actions on the central and peripheral parasympathetic nervous systems. Digoxin is therefore not as effective in ventricular rate control when catecholamines are increased. In addition, the effectiveness of digoxin varies with the individual patient's autonomic tone.

Digoxin is not effective in converting atrial fibrillation to sinus rhythm. In a placebo-controlled study in which 36 patients with recent onset of atrial fibrillation were randomized to receive either placebo or digoxin, no difference was apparent in conversion rates between the two groups.16 Therefore, digoxin cannot be recommended for the acute conversion of atrial fibrillation and should be considered second-line therapy for rate control of atrial fibrillation, with the possible exception of use in patients with decreased left ventricular function.17

When the heart rate is controlled acutely, oral calcium channel blockers, beta blockers and digoxin may be used alone or in combination (Table 2). In chronic rate control, digoxin controls the resting heart rate but often fails to control the ventricular rate during exercise.18

TABLE 2

Agents Used for Heart Rate Control

Agent Loading dose Onset of action Maintenance dosage Major side effects

Digoxin (Lanoxin)

0.25 mg IV or orally every 2 hours, up to 1.5 mg

5 to 30 minutes for IV therapy or 30 minutes to 2 hours for oral therapy

0.125 to 0.25 mg every day (oral or IV)

Digitalis toxicity, heart block, bradycardia

Diltiazem (Cardizem)

0.25 mg per kg IV over 2 minutes

2 to 7 minutes

10 to 15 mg per hour IV or 120 to 360 mg orally every day in divided doses

Hypotension, heart block, heart failure

Verapamil (Calan, Isoptin)

0.075 to 0.15 mg per kg IV over 2 minutes

3 to 5 minutes

240 to 360 mg orally every day in divided doses

Hypotension, heart block, heart failure

Esmolol (Brevibloc)

0.5 mg per kg IV over one minute

5 minutes

0.05 to 0.2 mg per kg per minute IV

Hypotension, heart block, bradycardia, asthma, heart failure

Metoprolol (Lopressor)*

2.5 to 5 mg IV bolus over 2 minutes, up to 3 doses

5 minutes

50 to 200 mg orally every day in divided doses

Hypotension, heart block, bradycardia, asthma, heart failure

Propranolol (Inderal)

0.15 mg per kg

5 minutes

40 to 320 mg orally every day in divided doses

Hypotension, heart block, bradycardia, asthma, heart failure


IV = intravenous.

*—Although metroprolol is indicated by the U.S. Food and Drug Administration for use in hypertension, angina pectoris and acute myocardial infarction, it is commonly used for rate control in atrial fibrillation.

TABLE 2   Agents Used for Heart Rate Control

View Table

TABLE 2

Agents Used for Heart Rate Control

Agent Loading dose Onset of action Maintenance dosage Major side effects

Digoxin (Lanoxin)

0.25 mg IV or orally every 2 hours, up to 1.5 mg

5 to 30 minutes for IV therapy or 30 minutes to 2 hours for oral therapy

0.125 to 0.25 mg every day (oral or IV)

Digitalis toxicity, heart block, bradycardia

Diltiazem (Cardizem)

0.25 mg per kg IV over 2 minutes

2 to 7 minutes

10 to 15 mg per hour IV or 120 to 360 mg orally every day in divided doses

Hypotension, heart block, heart failure

Verapamil (Calan, Isoptin)

0.075 to 0.15 mg per kg IV over 2 minutes

3 to 5 minutes

240 to 360 mg orally every day in divided doses

Hypotension, heart block, heart failure

Esmolol (Brevibloc)

0.5 mg per kg IV over one minute

5 minutes

0.05 to 0.2 mg per kg per minute IV

Hypotension, heart block, bradycardia, asthma, heart failure

Metoprolol (Lopressor)*

2.5 to 5 mg IV bolus over 2 minutes, up to 3 doses

5 minutes

50 to 200 mg orally every day in divided doses

Hypotension, heart block, bradycardia, asthma, heart failure

Propranolol (Inderal)

0.15 mg per kg

5 minutes

40 to 320 mg orally every day in divided doses

Hypotension, heart block, bradycardia, asthma, heart failure


IV = intravenous.

*—Although metroprolol is indicated by the U.S. Food and Drug Administration for use in hypertension, angina pectoris and acute myocardial infarction, it is commonly used for rate control in atrial fibrillation.

Rate control is necessary in all patients. Rate control may be achieved through cardioversion alone, but in patients who are not candidates for cardioversion or in whom cardioversion is unsuccessful, rate control is indicated in order to avoid tachycardia-induced cardiomyopathy.

Pharmacologic Methods of Acute Cardioversion

Several pharmacologic agents may be used for acute cardioversion in patients with atrial fibrillation, including oral and intravenous medications. These medications are compared in Table 3. It is important to note that all methods of pharmacologic cardioversion are associated with proarrhythmic risks. The incidence of polymorphic ventricular tachycardia may be as high as 2 percent, even with the use of oral agents. Therefore, we recommend that medical cardioversion be performed only in a monitored setting with an accessible defibrillator. After successful cardioversion, it is necessary to observe patients. We recommend continued observation until the QT interval normalizes, or for four to five half-lives.

TABLE 3

Comparison of Antiarrhythmic Therapies

Class of agent Agent Dosage Acute conversion rate (%) Time until cardioversion Chronic efficacy (%)

IA

Procainamide (Procainamide Hydrochloride Injection)

10 to 15 mg per kg IV, at 25 mg per minute

20

1 hour

50

Quinidine (Quinaglute)

324 to 648 mg orally every 8 hours

38 to 86

3 to 6 hours

47 to 60

IC

Propafenone (Rythmol)

600 mg orally as a single bolus dose; 150 to 300 mg three times daily as a maintenance dose

51 to 76

3 to 8 hours

50 to 60

Flecainide (Tambocor)

300 to 400 mg orally as a single bolus dose; 50 to 150 mg twice daily as a maintenance dose

68 to 91

3 to 8 hours

40 to 74

III

Amiodarone (Cordarone)

150 mg IV over 10 minutes, then 30 to 60 mg IV per hour; 200 to 400 mg orally every day as a maintenance dose after loading

43 to 68

8 to 24 hours

55 to 65

Sotalol (Betapace)

160 to 320 mg orally daily in two doses

20 to 52

3 to 6 hours

50 to 60

Ibutilide (Corvert)

0.01 mg per kg IV for patients under 60 kg (132 lb), 1 mg for patients over 60 kg, over 10 minutes*

33 to 45

1 hour

N/A

Other treatment

DC cardioversion

100 to 360 joules

67 to 94

Immediate

N/A


IV = intravenous; N/A = not available; DC = direct current.

*—Dose may be repeated once after 30 minutes if the patient has not converted to sinus rhythm after the first dose.

TABLE 3   Comparison of Antiarrhythmic Therapies

View Table

TABLE 3

Comparison of Antiarrhythmic Therapies

Class of agent Agent Dosage Acute conversion rate (%) Time until cardioversion Chronic efficacy (%)

IA

Procainamide (Procainamide Hydrochloride Injection)

10 to 15 mg per kg IV, at 25 mg per minute

20

1 hour

50

Quinidine (Quinaglute)

324 to 648 mg orally every 8 hours

38 to 86

3 to 6 hours

47 to 60

IC

Propafenone (Rythmol)

600 mg orally as a single bolus dose; 150 to 300 mg three times daily as a maintenance dose

51 to 76

3 to 8 hours

50 to 60

Flecainide (Tambocor)

300 to 400 mg orally as a single bolus dose; 50 to 150 mg twice daily as a maintenance dose

68 to 91

3 to 8 hours

40 to 74

III

Amiodarone (Cordarone)

150 mg IV over 10 minutes, then 30 to 60 mg IV per hour; 200 to 400 mg orally every day as a maintenance dose after loading

43 to 68

8 to 24 hours

55 to 65

Sotalol (Betapace)

160 to 320 mg orally daily in two doses

20 to 52

3 to 6 hours

50 to 60

Ibutilide (Corvert)

0.01 mg per kg IV for patients under 60 kg (132 lb), 1 mg for patients over 60 kg, over 10 minutes*

33 to 45

1 hour

N/A

Other treatment

DC cardioversion

100 to 360 joules

67 to 94

Immediate

N/A


IV = intravenous; N/A = not available; DC = direct current.

*—Dose may be repeated once after 30 minutes if the patient has not converted to sinus rhythm after the first dose.

Type IA Medications: Procainamide and Quinidine

Intravenous procainamide (Procainamide Hydrochloride Injection) is effective in cardioversion in up to 60 percent of patients in uncontrolled series. In one hour, the conversion rate to sinus rhythm is only 20 percent.19 Procainamide's main side effects include hypotension and QRS and QT prolongation in patients with torsades de pointes.

Oral quinidine (Quinaglute) also may be used for the acute termination of atrial fibrillation. The conversion rate is reported to be up to 60 percent. Torsades de pointes is a major side effect in patients who undergo therapy with quinidine, as it is with procainamide therapy. It appears that episodes of torsades de pointes are most likely to occur after reversion to sinus rhythm.20

Class IC Medications: Flecainide and Propafenone

Initial studies of oral flecainide (Tambocor) have demonstrated its efficacy and safety in the treatment of atrial tachycardia and atrial fibrillation.21 A single high-bolus dose of oral flecainide (less than 400 mg within three hours) has a conversion rate of 60 to 70 percent at three hours after treatment and up to 91 percent at eight hours.22,23

High-dose (600 mg) oral propafenone (Rythmol) has also been shown to be effective for cardioversion of atrial fibrillation, with conversion rates of up to 76 percent at eight hours after treatment. 23,24

Class III Medications: Amiodarone, Sotalol and Ibutilide

Unlike the class I agents, amiodarone (Cordarone) does not appear to be more effective than placebo in converting recent-onset atrial fibrillation to sinus rhythm, although patients who are treated with amiodarone tend to have a more controlled heart rate.2527 It is believed that intravenous amiodarone has little effect in atrial tissue. Side effects of intravenous amiodarone include hypotension and bradyarrhythmias. On the other hand, oral amiodarone, which prolongs atrial refractoriness, may be effective in cardioversion, either alone or as an adjunct to DC cardioversion.28 Unfortunately, it is not useful for acute cardioversion.29

Sotalol (Betapace) also is not useful for the acute termination of atrial fibrillation, probably because it tends to prolong atrial refractoriness more at a slow rate than during tachycardia.30

It should be noted that sotalol and amiodarone slow conduction and prolong refractoriness in the atrioventricular node and thus can control ventricular response to atrial fibrillation.31,32 In cases requiring the use of these drugs for chronic maintenance therapy, another atrioventricular nodal blocking agent is generally not necessary.

Ibutilide (Corvert) is a new intravenous class III antiarrhythmic agent. Unlike amiodarone and sotalol, it is currently indicated for the acute termination of atrial fibrillation and flutter. Ibutilide prolongs repolarization of the atrial tissue by enhancing the slow inward depolarizing Na+ current in the plateau phase of repolarization. Ibutilide has little to no effect on the conduction velocity of the atrial tissue.33 The electrophysiologic actions of ibutilide make it difficult for the atrial tissue to support multiple wavelets of reentry. Furthermore, the electrophysiologic effects of ibutilide are maintained at fast heart rates.

The half-life of ibutilide is three to six hours. It undergoes hepatic metabolization to one slightly active compound and seven inactive compounds.33 Its clinical effect, as measured by the QTc duration, is gone in two to six hours.33

Ibutilide is administered in a dosage of 0.01 mg per kg intravenously over 10 minutes. Conversion rates are between 33 and 45 percent within the first 70 minutes. Up to 70 percent of all conversions occur within 20 minutes of infusion.34,35 If the first dose is ineffective, a second may be administered before alternative strategies are considered.

Side effects include significant QT prolongation with sustained polymorphic ventricular tachycardia (torsades de pointes) in 1.7 percent of patients and nonsustained polymorphic ventricular tachycardia in 2.6 percent of patients.33,35 A four-hour observation period is recommended in patients who have received ibutilide.

In summary, class IA and class IC agents are effective for acute termination of atrial fibrillation, with conversion rates of 60 to 80 percent at eight hours after treatment. Although class III agents are useful as adjuncts to electric cardioversion and are effective in maintaining sinus rhythm, only ibutilide is useful for acute cardioversion. Placebo conversion rates range from 18 to 78 percent,2224 with the highest conversion rate occurring at eight hours after treatment.

Final Comment

The acute management of atrial fibrillation depends on the patient and the clinical situation. Patients who are clinically unstable should undergo immediate cardioversion. In hemodynamically stable patients, pharmacologic measures to control the heart rate, which may include intravenous or oral agents (or both), may be used. In an outpatient clinic where intravenous administration of medications and electrocardiographic and blood pressure monitoring are available, the heart rate may be controlled initially with intravenous medications. Oral agents may be used in ambulatory patients, provided that symptoms do not warrant prompt rate control.

If atrial fibrillation has been present for less than 48 hours, it is not necessary for the patient to undergo anticoagulation before cardioversion. Because of atrial stunning, a short (three- to four-week) course of warfarin, maintaining the INR between 2.0 and 3.0, should be used after cardioversion (both DC and pharmacologic). If atrial fibrillation has been present for more than 48 hours or if the onset is unknown, an initial three- to six-week course of anticoagulation is recommended. Patients with chronic atrial fibrillation (including paroxysmal fibrillation) and at least one risk factor for thromboembolism should be considered for chronic anticoagulation.

Three large, prospective, randomized trials currently under way address the question of rate control versus rhythm control. Until the results of these trials are available, the decision for patients to undergo cardioversion for atrial fibrillation and to attempt to maintain sinus rhythm should be based on the patient's symptoms and risk for thromboembolism. Most patients benefit from at least one attempt at maintaining sinus rhythm. In patients with persistent atrial fibrillation, cardioversion should be considered as soon as possible (i.e., within 48 hours for an acute episode or within three to four weeks if the patient requires initial anticoagulation), since evidence indicates that the duration of arrhythmia is related to the likelihood of recurrence. Patients with paroxysmal atrial fibrillation do not require cardioversion by definition, although they may require medication to control heart rate and often require antiarrhythmic agents to maintain sinus rhythm.

In patients with persistent atrial fibrillation, several intravenous and oral pharmacologic alternatives to DC cardioversion are available. Care must be used in cardioversion, since all methods carry a significant risk of potentially lethal proarrhythmia. All cardioversions, whether pharmacologic or DC, must be performed in a monitored setting with an available external cardioverter/defibrillator and staff members who are certified in Advanced Cardiac Life Support.

Since torsades de pointes occurs in the period after cardioversion, patients must be monitored for up to 24 hours depending on the method of cardioversion used. There are no data to support outpatient cardioversion with high- or moderate-dose oral antiarrhythmics without the use of electrocardiographic monitoring and close observation. Torsades de pointes remains a significant risk, so the safety of this method has not been established.

The Authors

JOSEPH T. DELL'ORFANO, M.D., is a postdoctoral fellow in cardiac electrophysiology at the Milton S. Hershey Medical Center, Hershey, Pa. He received a medical degree from the University of Connecticut School of Medicine, Farmington, and served a residency in internal medicine at the University of Connecticut Health Center.

JERRY C. LUCK, M.D., is associate professor of medicine and director of electrophysiology at the Milton S. Hershey Medical Center. He received a medical degree from Temple University School of Medicine, Philadelphia. Dr. Luck served a residency in internal medicine at the Medical College of Pennsylvania, also in Philadelphia.

DEBORAH L. WOLBRETTE, M.D., is assistant professor of medicine and director of cardiac pacing and electrocardiography at the Milton S. Hershey Medical Center. She received her medical degree from the University of Texas at Austin and served a residency in internal medicine at the University of Texas Health Science Center at Houston.

HEMANTKUMAR PATEL, M.D., is a postdoctoral fellow in cardiac electrophysiology at the Milton S. Hershey Medical Center. Dr. Patel received a medical degree from Pennsylvania State University College of Medicine, Hershey, and served a residency in internal medicine at Emory University School of Medicine, Atlanta.

GERALD V. NACCARELLI, M.D., is professor of medicine and director of the Cardiovascular Center at the Milton S. Hershey Medical Center. He received a medical degree from Pennsylvania State University College of Medicine and served a residency in internal medicine at Bowman Gray School of Medicine of Wake Forest University, Winston-Salem, N.C.

Address correspondence to Gerald V. Naccarelli, M.D., Cardiology Section, Milton S. Hershey Medical Center, 500 University Dr., P.O. Box 850, Mail Stop HO47, Hershey, PA 17033-0850. Reprints are not available from the authors.

REFERENCES

1. Kannel WB, Abbott RD, Savage DD, McNamara M. Epidemiologic features of chronic atrial fibrillation: the Framingham study. N Engl J Med. 1982;306:1018–22.

2. Furberg CD, Psaty BM, Manolio TA, Gardin JM, Smith VE, Rautaharju PM. Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Am J Cardiol. 1994;74:236–41.

3. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994;154:1449–57.

4. Allessie MA, Konings K, Kirchhof CJ, Wijffels M. Electrophysiologic mechanisms of perpetuation of atrial fibrillation. Am J Cardiol. 1996;77:10A–23A.

5. Disch DL, Greenberg ML, Holzberger PT, Malenka DJ, Birkmeyer JD. Managing chronic atrial fibrillation: a Markov decision analysis comparing warfarin, quinidine, and low-dose amiodarone. Ann Intern Med. 1994;120:449–57.

6. Falk RH. Proarrhythmia in patients treated for atrial fibrillation or flutter. Ann Intern Med. 1993;117:141–50 [Published erratum appears in Ann Intern Med. 1992;117:446]

7. Roden DM. Risks and benefits of antiarrhythmic therapy. N Engl J Med. 1994;331:785–91.

8. Atrial fibrillation follow-up investigation of rhythm management—the AFFIRM study design. Am J Cardiol. 1997;79:1198–202.

9. Weigner MJ, Caulfield TA, Danias PG, Silverman DI, Manning WJ. Risk for clinical thromboembolism associated with conversion to sinus rhythm in patients with atrial fibrillation lasting less than 48 hours. Ann Intern Med. 1997;126:615–20.

10. Omran H, Jung W, Rabahieh R, Schimpf R, Wolpert C, Hagendorff A, et al. Left atrial chamber and appendage function after internal atrial defibrillation: a prospective and serial transesophageal echocardiographic study. J Am Coll Cardiol. 1997;29:131–8.

11. Prystowsky EN, Benson DW Jr, Fuster V, Hart RG, Kay GN, Myerburg RJ, et al. Management of patients with atrial fibrillation. A statement for healthcare professionals. The Subcommittee on Electrocardiography and Electrophysiology, American Heart Association. Circulation. 1996;93:1262–77.

12. Manning WJ, Silverman DI, Keighley CS, Oettgen P, Douglas PS. Transesophageal echocardiographically facilitated early cardioversion from atrial fibrillation using short-term anticoagulation: final results of a prospective 4.5-year study. J Am Coll Cardiol. 1995;25:1354–61.

13. Seto TB, Taira DA, Tsevat J, Manning WJ. Cost-effectiveness of transesophageal echocardiographic-guided cardioversion: a decision analytic model for patients admitted to the hospital with atrial fibrillation. J Am Coll Cardiol. 1997;29:122–30.

14. Fatkin D, Kuchar DL, Thorburn CW, Feneley MP. Transesophageal echocardiography before and during direct current cardioversion of atrial fibrillation: evidence for “atrial stunning” as a mechanism of thromboembolic complications. J Am Coll Cardiol. 1994;23:307–16.

15. Watanabe AM. Digitalis and the autonomic nervous system. J Am Coll Cardiol. 1985;5:35A–42A.

16. Falk RH, Knowlton AA, Bernard SA, Gotlieb NE, Battinelli NJ. Digoxin for converting recent-onset atrial fibrillation to sinus rhythm. A randomized, double-blinded trial. Ann Intern Med. 1987;106:503–6.

17. Sarter BH, Marchlinski FE. Redefining the role of digoxin in the treatment of atrial fibrillation. Am J Cardiol. 1992;69:71G–8G.

18. Rawles JM, Metcalfe MJ, Jennings K. Time of occurrence, duration, and ventricular rate of paroxysmal atrial fibrillation: the effect of digoxin. Br Heart J. 1990;63:225–7.

19. Volgman AS, Stambler BS, Kappagoda C, Carberry PA, Dunn G, Perry KT, et al. Comparison of intravenous ibutilide versus procainamide for the rapid termination of atrial fibrillation or flutter. Electrophysiology, 17th Annual Scientific Sessions; 1996 May 15–18; Seattle. Pacing Clin Electrophysiol. 1996;19(4 Pt 1):608.

20. Hohnloser SH, van de Loo A, Baedeker F. Efficacy and proarrhythmic hazards of pharmacologic conversion of atrial fibrillation: prospective comparison of sotalol versus quinidine. J Am Coll Cardiol. 1995;26:852–8.

21. Berns E, Rinkenberger RL, Jeang MK, Dougherty AH, Jenkins M, Naccarelli GV. Efficacy and safety of flecainide acetate for atrial tachycardia or fibrillation. Am J Cardiol. 1987;59:1337–41.

22. Capucci A, Lenzi T, Boriani G, Trisolino G, Binetti N, Cavazza M, et al. Effectiveness of loading oral flecainide for converting recent-onset atrial fibrillation to sinus rhythm in patients without organic heart disease or with only systemic hypertension. Am J Cardiol. 1992;70:69–72.

23. Capucci A, Boriani G, Botto GL, Lenzi T, Rubino I, Falcone C, et al. Conversion of recent-onset atrial fibrillation by a single oral loading dose of propafenone or flecainide. Am J Cardiol. 1994;74:503–5.

24. Boriani G, Biffi M, Capucci A, Botto GL, Broffoni T, Rubino I, et al. Oral propafenone to convert recent-onset atrial fibrillation in patients with and without underlying heart disease. A randomized, controlled trial. Ann Intern Med. 1997;126:621–5.

25. Horner SM. A comparison of cardioversion of atrial fibrillation using oral amiodarone, intravenous amiodarone and DC cardioversion. Acta Cardiol. 1992;47:473–80[Published erratum appears in Acta Cardiol 1992;47:following table of contents]

26. Galve E, Rius T, Ballester R, Artaza MA, Arnau JM, Garcia-Dorado D, et al. Intravenous amiodarone in treatment of recent-onset atrial fibrillation: results of a randomized, controlled study. J Am Coll Cardiol. 1996;27:1079–82.

27. Donovan KD, Power BM, Hockings BE, Dobb GJ, Lee KY. Intravenous flecainide versus amiodarone for recent-onset atrial fibrillation. Am J Cardiol. 1995;75:693–7.

28. Tieleman RG, Gosselink AT, Crijns HJ, vanGelder IC, van den Berg MP, de Kam PJ, et al. Efficacy, safety, and determinants of conversion of atrial fibrillation and flutter with oral amiodarone. Am J Cardiol. 1997;79:53–7.

29. Skoularigis J, Rothlisberger C, Skudicky D, Essop MR, Wisenbaugh T, Sareli P. Effectiveness of amiodarone and electrical cardioversion for chronic rheumatic atrial fibrillation after mitral valve surgery. Am J Cardiol. 1993;72:423–7.

30. Halinen MO, Huttunen M, Paakkinen S, Tarssanen L. Comparison of sotalol with digoxin-quinidine for conversion of acute atrial fibrillation to sinus rhythm (the Sotalol-Digoxin-Quinidine Trial). Am J Cardiol. 1995;76:495–8.

31. Juul-Moller S, Edvardsson N, Rehnqvist-Ahlberg N. Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation. Circulation. 1990;82:1932–9.

32. Hou ZY, Chang MS, Chen CY, Tu MS, Lin SL, Chiang HT, et al. Acute treatment of recent-onset atrial fibrillation and flutter with a tailored dosing regimen of intravenous amiodarone. A randomized, digoxin-controlled study. Eur Heart J. 1995;16:521–8.

33. Naccarelli GV, Lee KS, Gibson JK, VanderLugt J. Electrophysiology and pharmacology of ibutilide. Am J Cardiol. 1996;78:12–6.

34. Ellenbogen KA, Clemo HF, Stambler BS, Wood MA, VanderLugt JT. Efficacy of ibutilide for termination of atrial fibrillation and flutter. Am J Cardiol. 1996;78:42–5.

35. Ellenbogen KA, Stambler BS, Wood MA, Sager PT, Wesley RC Jr, Meissner MC, et al. Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter: a dose-response study. J Am Coll Cardiol. 1996;28:130–6.

Richard W. Sloan, M.D., R.PH., coordinator of this series, is chairman and residency program director of the Department of Family Medicine at York (Pa.) Hospital and clinical associate professor in family and community medicine at the Milton S. Hershey Medical Center, Pennsylvania State University, Hershey, Pa.


Copyright © 1998 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions


Article Tools

  • Print page
  • Share this page
  • AFP CME Quiz

Information From Industry

More in Pubmed

Navigate this Article